PMID- 21611869
OWN - NLM
STAT- MEDLINE
DCOM- 20120424
LR  - 20211020
IS  - 1435-4373 (Electronic)
IS  - 0934-9723 (Linking)
VI  - 31
IP  - 2
DP  - 2012 Feb
TI  - Therapeutic drug monitoring of posaconazole in hematology adults under 
      posaconazole prophylaxis: influence of food intake.
PG  - 161-7
LID - 10.1007/s10096-011-1288-9 [doi]
AB  - Posaconazole (PCZ) is given at 200 mg three times daily as a fungal prophylaxis 
      in neutropenic hematologic malignancy patients. A relationship between exposure, 
      plasma concentration, and efficacy is suggested. The objectives of this 
      prospective study were to analyze the PCZ plasma concentration in hematology 
      adults at high risk of developing invasive fungal infections (IFIs), and factors 
      that could have an impact on the PCZ plasma concentration. PCZ plasma 
      concentrations were measured after 2, 7, 10, 14, and 21 days of PCZ prophylaxis. 
      Factors such as gender, age, body weight, posology, treatment duration, 
      mucositis, proton pump inhibitor (PPI) use, and food intake were studied. 
      Sixty-three patients were included, with a median age of 52 years (range 17-70) 
      and a median weight of 75 kg (range 47-150). The median PCZ plasma concentration 
      of the 63 patients ranged from 0.42 to 0.48 mg/L. At day 2, 30% of PCZ plasma 
      concentration were under 0.35 mg/L, and at day 7, 74% were <0.70 mg/L. PCZ plasma 
      concentrations were not affected by gender, age, body weight, or treatment 
      duration. We found that food intake had a high influence on PCZ plasma 
      concentrations (p = 0.0049). PCZ was well tolerated. One patient has developed a 
      probable IFI, probably related to a low exposure to PCZ. PCZ therapeutic drug 
      monitoring (TDM) is essential in order to early detect patients with low 
      concentrations, to assess the etiology of such results, and to decide on the 
      treatment strategy to apply.
FAU - Eiden, C
AU  - Eiden C
AD  - Department of Medical Pharmacology and Toxicology, University Hospital of 
      Montpellier, Montpellier, France. c-eiden@chu-montpellier.fr
FAU - Meniane, J C
AU  - Meniane JC
FAU - Peyriere, H
AU  - Peyriere H
FAU - Eymard-Duvernay, S
AU  - Eymard-Duvernay S
FAU - Le Falher, G
AU  - Le Falher G
FAU - Ceballos, P
AU  - Ceballos P
FAU - Fegueux, N
AU  - Fegueux N
FAU - Cociglio, M
AU  - Cociglio M
FAU - Reynes, J
AU  - Reynes J
FAU - Hillaire-Buys, D
AU  - Hillaire-Buys D
LA  - eng
PT  - Journal Article
DEP - 20110526
PL  - Germany
TA  - Eur J Clin Microbiol Infect Dis
JT  - European journal of clinical microbiology & infectious diseases : official 
      publication of the European Society of Clinical Microbiology
JID - 8804297
RN  - 0 (Antifungal Agents)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Triazoles)
RN  - 6TK1G07BHZ (posaconazole)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antifungal Agents/administration & dosage/adverse 
      effects/*pharmacokinetics/*therapeutic use
MH  - Antineoplastic Agents/therapeutic use
MH  - Chemoprevention
MH  - Drug Monitoring/*methods
MH  - *Eating
MH  - Female
MH  - Hematologic Neoplasms/*complications/drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mycoses/*prevention & control
MH  - Triazoles/administration & dosage/adverse effects/*pharmacokinetics/*therapeutic 
      use
MH  - Young Adult
EDAT- 2011/05/26 06:00
MHDA- 2012/04/25 06:00
CRDT- 2011/05/26 06:00
PHST- 2011/02/15 00:00 [received]
PHST- 2011/04/26 00:00 [accepted]
PHST- 2011/05/26 06:00 [entrez]
PHST- 2011/05/26 06:00 [pubmed]
PHST- 2012/04/25 06:00 [medline]
AID - 10.1007/s10096-011-1288-9 [doi]
PST - ppublish
SO  - Eur J Clin Microbiol Infect Dis. 2012 Feb;31(2):161-7. doi: 
      10.1007/s10096-011-1288-9. Epub 2011 May 26.